Superpower peptides available for pre-order. Get first access.

Peptide science

Is dermorphin addictive?

Whether dermorphin is addictive has never been tested in people. See what rat studies show on dependence, overdose, and breathing risk.

Quick answer

No human study has measured whether dermorphin is addictive. It is a potent, selective mu-opioid agonist, the receptor class that produces dependence and respiratory depression. Early rat work found tolerance and dependence less marked than with morphine, but that is not human evidence. Dermorphin was about 39 times more potent than morphine in one assay, which makes overdose a real risk. It is not FDA-approved.

Published
November 12, 2026
Last updated
November 12, 2026

Dermorphin is a potent opioid with untested addiction risk

Whether dermorphin is addictive has never been tested in people. Dermorphin acts as a selective mu-opioid receptor agonist1, the same target morphine works through. Opioid drugs that activate that receptor produce physical dependence, addiction, and respiratory depression2. Dermorphin is also not an FDA-approved drug3. The measurements that do exist were made in rats, decades ago.

What animal studies show about dermorphin dependence

Rats infused with dermorphin into the brain ventricles developed tolerance and showed withdrawal after naloxone4, a drug that blocks opioid receptors. In that work, tolerance and physical dependence were both less marked than with morphine4.

Tolerance means needing more of a drug for the same effect, and physical dependence means withdrawal symptoms when the drug stops. Neither is the compulsive use that defines addiction5.

Those results come from rats dosed directly into the brain, which says little about repeated exposure in people. In people, the same question has never been put to a study.

Dermorphin's abuse potential in people is unmeasured

Dermorphin's abuse potential in people is unknown, because no registered human trial of dermorphin exists6. Abuse liability gets established through human laboratory studies with standardized outcome measures7. Those studies belong to the drug-development pathway8, which dermorphin never entered.

One 1985 surgical trial is the whole human record. That trial measured pain relief and how often side effects occurred9. Dermorphin never returned to clinical use10 afterwards. No study has characterized dermorphin's subjective effects in people. That gap does not lower the risk a mu-opioid agonist carries.

Overdose and slowed breathing are the main acute risks

With any mu-opioid agonist, the acute danger is respiratory depression, the proximal cause of death in opioid overdose11. Respiratory depression means breathing too slow and shallow to supply enough oxygen.

Dermorphin was about 39 times more potent than morphine4 on guinea-pig ileum, an isolated-tissue assay. That potency leaves little margin for error.

An unregulated product also makes the amount taken unknowable. Only 23 of 44 products12 sold online as selective androgen receptor modulators matched their labeled class. Semaglutide vials test-purchased from unlicensed online sellers fell far below their labeled purity13. Neither market is dermorphin, though both show how little an unapproved label guarantees.

Researchers are redesigning dermorphin into hybrid peptides

Dermorphin now serves mainly as a starting structure for new molecules. Chemists use it as the mu-opioid half of a hybrid ligand14.

In non-human primates, mixed nociceptin and mu partial agonists produced analgesia without signs of abuse liability15. A dermorphin-ranatensin hybrid relieved pain in mice without the withdrawal syndrome morphine produced16. Both remain research compounds, so today's opioid risk still belongs to the drugs already in circulation.

Groups at higher risk from a mu-opioid agonist

A mu-opioid agonist is most dangerous for people whose margin is already narrow. Each figure here comes from prescription or illicit opioid research, not dermorphin.

Dermorphin itself has never been studied in any of these groups.

Where can I learn about peptides?

Superpower’s peptide library covers opioid peptides like dermorphin alongside the wider peptide families, including what has and has not been studied in people.

A team of health journalists and licensed clinicians writes and fact-checks every guide, including the science behind peptides, which explains how these molecules are built and tested.

IMPORTANT SAFETY INFORMATION

Dermorphin is not approved by the FDA for any medical use. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. Dermorphin is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.

Dermorphin is a selective mu-opioid receptor agonist. Based on that mechanism, the following considerations apply to any exposure context: respiratory depression, sedation, nausea and vomiting, tolerance and physical dependence with repeated exposure, and an unpredictable dose response from unregulated sources. Its addiction potential in humans has never been characterized, and the absence of that research is not evidence of safety.

Dermorphin should not be used by anyone outside an IRB-approved clinical research study. No FDA-approved indication, label, or human dosing protocol exists. Populations of particular concern, based on the mu-opioid agonist mechanism and the absence of human safety data, include: individuals with respiratory compromise or sleep apnea; individuals with a history of opioid use disorder; individuals taking benzodiazepines, alcohol, or other CNS depressants; pregnant or breastfeeding individuals; and athletes subject to anti-doping testing. These are illustrative concerns, not a contraindication checklist.

Products labeled as dermorphin and sold through online vendors are unregulated research chemicals with no safety oversight, and no pharmaceutical-grade formulation exists for human use. Long-term human safety data does not exist.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to dermorphin. Dermorphin is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science